Ridgeback Capital
Crossover fundMiami Β· SeedβLate Stage Β· 1 people tracked
Also known as MANDALAY FINANCIAL, L.L.C.
Investment thesis
Ridgeback Capital invests in private and public healthcare companies dedicated to developing transformative, life-saving and life-changing therapies. The firm emphasizes patient capital, reflecting founder Dr. Wayne Holman's belief that meaningful healthcare advances often take many years to materialize and require long-term backing for new technologies and companies to succeed. Over more than two decades, the firm's principal has funded over 100 public and private biopharma companies supporting research and development addressing unmet medical needs.
Source: firm website, verified Aug 3, 2026.
Team Β· 1 people
from the firm's websiteWhat they invest in
from 11 of 19 portfolio companiesBiotech Γ11Healthtech Γ9Medical Devices Γ5Digital Health Γ2Deep Tech Γ1
HQs:United StatesΓ6
Investments Β· 19 tracked
founders shown can be your intro pathBy year:2024 Β· 12016 Β· 12014 Β· 13 dated
MacroGenics is a clinical-stage biopharmaceutical company developing antibody-based therapies for cancer patients.
BiotechHealthtechMedical Devices
Co-investorsHavencrest Capital ManagementRiverVest Venture PartnersSanofi Ventures
Adaptimmune Therapeutics is a biotechnology company, though the specific focus of their therapeutic work is not detailed on this investors and media page.
BiotechHealthtechMedical Devices
Co-investorsAvoro Capital AdvisorsEight Roads VenturesF-Prime CapitalNew Enterprise Associates (NEA)
Co-investorsVedanta Capital
Patrick Mahaffy(Founder)in
Co-investorsAisling CapitalNew Enterprise Associates (NEA)
Gilead discovers, develops, and delivers innovative therapeutics for people with life-threatening diseases, focusing on virology, oncology, and inflammation across more than 35 countries.
BiotechDigital HealthHealthtechMedical DevicesFoster City, US
Lou Lange(Founder)Michael L. Riordan(Founder)inDaniel O'Dayin
Co-investorsAisling CapitalAsset Management CompanyFrazier Life SciencesKleiner PerkinsLongitude CapitalLumira Ventures+5 more
Kyntra Bio (formerly FibroGen) is a clinical-stage biopharmaceutical company developing therapies for oncology and rare diseases, including serious and life-threatening conditions.
BiotechHealthtechSan Francisco, US
Frank H. Valone(Executive Officer)Thomas F. Kearns(Director)K. Peony Yu(Executive Officer)Jorma Routti(Director)Miguel Madero(Director)Rory B. Riggs(Director)
Co-investorsAvalon BioVenturesScientia VenturesMaverick Ventures
GENFIT is a biopharmaceutical company developing therapies for rare, life-threatening liver diseases, with an R&D pipeline of eight programs focused on acute-on-chronic liver failure, hepatic encephalopathy, cholangiocarcinoma, and urea cycle disorders/organic acidemias.
BiotechHealthtech
Co-investorsredalpine
Hinge Bio is a biotechnology company developing next-generation therapeutics based on its GEM-DIMER platform, aimed at improving efficacy and reducing resistance and side effects.
BiotechHealthtechBurlingame, US
Daniel J. Capon(Director)Carin M. Rollins(Executive Officer, Director)Carin Mueller Rollins(Co-Founder & Chief Operating Officer)Harold E. Selick, PhD(Executive Officer, Director)Miriam Siekevitz(Executive Officer)Harold E. "Barry" Selick(Chief Executive Officer & Director)
Co-investorsPoint72Baruch Future VenturesInVivium CapitalAgent Capital
Intercept Pharmaceuticals is a biopharmaceutical company developing medicines for rare and serious liver diseases, with research centered on Farnesoid X Receptor (FXR) biology for conditions such as severe alcohol-associated hepatitis.
BiotechMedical Devices
Co-investorsAisling CapitalBioBritSamsara BioCapital
Ironwood Pharmaceuticals is a gastrointestinal (GI) healthcare company focused on developing treatments for GI diseases.
BiotechDigital HealthHealthtechCambridge, US
PETER M. HECHT(Executive Officer, Director)MARK G. CURRIE(Executive Officer)HALLEY E. GIBLERT(Executive Officer)THOMAS GRANEY(Executive Officer)THOMAS A. MCCOURT(Executive Officer)
BoardTERRANCE G. MCGUIRE(Director)
Co-investorsF-Prime CapitalMountain Group CapitalVenrockMaverick VenturesPolaris Partners
Regeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease.
BiotechHealthtechTarrytown, US
Co-investorsSanderling VenturesvenBio PartnersWireframe Ventures
Sangamo is a genomic medicine company using its proprietary zinc finger technology to develop gene therapies aimed at curing severe diseases, with a focus on neurology and rare disorders.
BiotechMedical Devices
Co-investorsCalifornia Technology VenturesFoothill VenturesForesite Capital
Co-investorsArtis VenturesThe Column Group
Co-investorsKleiner PerkinsSofinnova Ventures
Exits Β· 2
IPOs and acquisitions across the tracked portfolioMacrogenics IncNASDAQ: MGNXIntercept Pharmaceuticalsacq. by Alfasigma
Portfolio news
latest coverage across their companiesSangamo Therapeutics Β· tipranks.com Β· Aug 13, 2026
Ironwood Pharmaceuticals Β· marketbeat.com Β· Aug 11, 2026
Cellectis Β· investing.com Β· Aug 6, 2026
Adaptimmune Β· trial.medpath.com Β· Oct 27, 2025
Frequently asked questions
- How many investments has Ridgeback Capital made?
- Ridgeback Capital has 18 tracked investments, 1 of which have exited via acquisition or IPO.
- What stage does Ridgeback Capital invest at?
- Ridgeback Capital invests at the Seed, Late Stage stages.
- What sectors does Ridgeback Capital focus on?
- Ridgeback Capital focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Ridgeback Capital located?
- Ridgeback Capital is headquartered in Miami, US.
- Who does Ridgeback Capital co-invest with?
- Ridgeback Capital most often shares deals with Aisling Capital, Kleiner Perkins, New Enterprise Associates (NEA), among 32 tracked co-investors.
Similar investors
Sanderling Ventures is one of the oldest investment firms focused on building new biomedical companies, working in close partnership with entrepreneurs.
JSTAR Capital Investments is a healthcare-focused investment firm backing medical technology companies, providing capital and expert guidance to advance patient care and address global healthcare challenges.
T. Rowe Price is a global asset management firm that actively invests across markets to pursue opportunities on behalf of its clients.
New Leaf Venture Partners is a venture capital firm investing in innovative healthcare companies.
The JDRF T1D Fund is a venture philanthropy investor focused on type 1 diabetes (T1D), backing companies developing disease-modifying therapies and cures for the condition.